The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Repeat infusions of CD19 CAR-T
Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, talks on the deepening of responses in patients previously treated with CD19 CAR-T cells by using repeated infusions of the cellular therapy. Dr Gauthier goes on to outline how the use of fully humanized CAR-T cells may reduce immunogenicity. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
